Navigation Links
Ampio Pharmaceuticals, Inc. (AMPE) announces appointment of Josh Disbrow as Chief Operating Officer effective December 15, 2012
Date:11/28/2012

GREENWOOD VILLAGE, Colo., Nov. 28, 2012 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (AMPE), a biopharmaceutical company developing repurposed drugs and new molecular entities (NMEs) that treat inflammatory diseases, including osteoarthritis, diabetic macular edema (DME) and sexual dysfunction announced the appointment of Josh Disbrow as Chief Operating Officer of Ampio Pharmaceuticals, effective December 15, 2012.

(Logo:  http://photos.prnewswire.com/prnh/20120516/MM09116LOGO)

Mr. Disbrow was most recently the Vice President of Commercial Operations at Arbor Pharmaceuticals. He joined Arbor in 2007 as the company's second full time employee and led the company's commercial efforts from inception to $127 million in annual sales in 2011 at which time the company was sold to an investor group. Since the company's acquisition, Josh remained with Arbor and oversaw the growth of the company's commercial infrastructure to over 150 people in sales, marketing, and other commercial functions. During his time at Arbor, Josh also served as the company's commercial lead on all business and corporate development activities including in-licensing, out-licensing, partnering, mergers and acquisitions, and university collaborations.

Arbor began as an entrepreneurial venture with no products on the market. Through Josh's leadership Arbor developed into a fully integrated specialty pharmaceutical company with a focus on bringing novel prescription pharmaceuticals to market through efficient product development, aggressive business development, corporate partnerships, and efficient commercial scale-up.

Mr. Disbrow has spent 17 years in the pharmaceutical, diagnostic, and medical device industries and has held positions of increasing responsibility in sales, marketing, sales management, commercial operations, and commercial strategy.
'/>"/>

SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Champions Oncology Reports Financial Results for the Year Ended April 30, 2012
2. Champions Oncology Inc. Receives Approval from U.S. Regulatory Authorities
3. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
4. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Update and Reports Financial Results for Third Quarter 2012
5. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results
6. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess of $100,000 Investing In Keryx Biopharmaceuticals, Inc. To Contact the Firm
7. FierceBiotech Names Enanta Pharmaceuticals, Inc. a Fierce 15 Winner
8. Auxilium Pharmaceuticals, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference
9. MAP Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
10. Auxilium Pharmaceuticals, Inc. to Present At The JMP Securities 2012 Healthcare Conference
11. Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... , July 3, 2015 ... 22 september 2015 på  http://www.openinnovationinscience.at till ... in Science" som hålls i ... färsk undersökning med internationella forskare och vetenskapsmän ... är hälsovetenskapens två största utmaningar bristen på ...
(Date:7/2/2015)... , July 2, 2015 College of ... Eakins are gaining invaluable real-world experiences while serving ... this summer. The students will be working ... Wereszczynski,s research group at IIT. The internship came ... Tom Carter , Physics; Dr. Kathy Finan , ...
(Date:7/1/2015)... ... July 01, 2015 , ... It is now possible ... using single photon emission computed tomography (SPECT) according to researchers from Amen ... examined over 20,000 brain scans and is believed to be the largest brain imaging ...
(Date:7/1/2015)... , July 1, 2015   Neuraltus Pharmaceuticals, ... development of groundbreaking drugs to treat neurodegenerative diseases ... that Robert G. Miller , M.D., Director of ... Health,s California Pacific Medical Center in San Francisco, has ... for $1.5 million to help fund a Phase ...
Breaking Biology Technology:Lansering av världens första program för öppen innovation för att utbilda forskare 2Lansering av världens första program för öppen innovation för att utbilda forskare 3COD Students Participate in Prestigious Summer Internships 2Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 2Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 3Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 4Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4
... 5 NeurogesX, Inc.,(Nasdaq: NGSX ), a biopharmaceutical ... today announced it will,report results for its second quarter ... A conference call to review the results will ... 13, 2008 and will be hosted by Anthony DiTonno,President ...
... Chief Medical Officer of LabCorp and Jack Ballantyne, Forensic ... ... CARLSBAD, Calif., Aug. 5 GenVault Corporation today,announces ... and,Dr. Jack Ballantyne, have joined its Scientific Advisory Board. ...
... Aug. 5 Imaging,Diagnostic Systems, Inc., (OTC Bulletin Board: ... you know, I returned to the company three months ... of the Board; we have,received many phone calls from ... future. As my first priority, I have,recently secured a ...
Cached Biology Technology:NeurogesX to Report Second Quarter 2008 Financial Results 2NeurogesX to Report Second Quarter 2008 Financial Results 3GenVault Expands Scientific Advisory Board 2GenVault Expands Scientific Advisory Board 3CEO's Letter to Shareholders of Imaging Diagnostic Systems, Inc. 2CEO's Letter to Shareholders of Imaging Diagnostic Systems, Inc. 3CEO's Letter to Shareholders of Imaging Diagnostic Systems, Inc. 4
(Date:6/23/2015)... PALM BEACH GARDENS, Fla. , June ... of multi-factor identity management and authentication solutions, today ... Altus strong, multi-factor authentication solution.  The ... ease of use of the DigitalPersona Altus ... and biometric reader compatibility. In ...
(Date:6/17/2015)... Maryland , and HILDEN, Germany , ... QGEN ; Frankfurt Prime Standard: QIA) today launched new ... evidence in forensic laboratories in the United States ... solution to simultaneously analyze multiple key genomic markers (short tandem ... ® Quality Sensor to evaluate the quality of DNA ...
(Date:6/16/2015)... -- With the increasing number and severity of data breaches ... recent compromise of Federal employee data from OPM,s ... government agencies. HYPR Corp. announced today that ... has been submitted for testing and approval of Federal ... tamper proofing. The proliferation of security ...
Breaking Biology News(10 mins):Crossmatch Releases Enhanced DigitalPersona Altus Advanced Authentication Functionality 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 4QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 5Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 2Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 3
... molecule, in which molecules and molecular complexes are ... to come into its own with the emergence ... of the attention because of their appetite for ... the field supramolecular organic frameworks (SOFs). Researchers ...
... 2013) Ribbons of ultrathin graphene combined with polyurethane paint ... radar domes, according to scientists at Rice University. ... Lockheed Martin, developed the compound to protect marine and airborne ... radio frequencies. The research was published this week ...
... (OI) is a congenital bone disease that causes stunted ... fractures already in the fetus, and now an international ... treated two babies in utero by injecting bone-forming stem ... in the journal Stem Cells Translational Medicine . ...
Cached Biology News:SOFS take to water 2SOFS take to water 3Graphene nanoribbons an ice-melting coat for radar 2Graphene nanoribbons an ice-melting coat for radar 3Brittle-bone babies helped by fetal stem cell grafts 2
... ejector is a unique product that facilitates ... their holder. Linkage: This CLS number is ... match Cornings product number. If showing no ... Sigma-Aldrich number (Z71,314-7) or contact customer service ...
...
... ideal modular cleanroom for biological safety ... require cleanliness (to Class 10/ISO 3) ... to create ultra-smooth surfaces that are ... One-inch radius corners simplify cleaning. Unique ...
This free-standing work station safely ventilates fumes upwards, away from the work surface. Optional Exhaust Purification System features bonded charcoal filters that remove organic chemical vapors ...
Biology Products: